Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

ValiRx PLC

VAL.L ✓ COMPLIANT ☆ Track — members

LSE · Healthcare · Biotechnology & Medical Research ·

UK Micro Cap Analyst: N/A

Last Close

$0.00

▲ +0.00%

Market Cap $2.85M · Vol 2.16M

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$2.85M

Micro Cap

Div Yield

N/A

Semi-annual dividend

EPS Growth

N/A

YoY

RSI (14)

50.00

Momentum

Beta

-0.96

vs Market

52W High

$0.01

81.02% below

52W Low

$0.00

24.22% above

Volume

2.16M

Avg 23.08M

P/B

0.87

Price-to-book

ROE

N/A

Return on equity

Free Float

91.05%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, ValiRx PLC (VAL.L) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does VAL.L pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.00%

+10.34%

-33.61%

-51.52%

YTD

-52.24%

-69.52%

-97.57%

-99.12%

Financials & Valuation

TTM · Annual

Total Revenue	$42.27K
Net Income	$-3,083,923.00
Revenue Growth (YoY)	-36.97%
Gross Margin	-19.92%
Operating Margin	-5,809.21%
Net Profit Margin	-7,296.26%
ROE	N/A
ROA · ROIC	-70.07% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	44.16
P/B	0.87
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	1.32B

Technical Indicators

50-Day SMA	$0.00
200-Day SMA	$0.00
RSI (14)	50.00
Beta	-0.96
52-Week High	$0.01
52-Week Low	$0.00

Volume Today	2.16M
Avg Daily Volume (30D)	23.08M
Relative Volume	0.09x
Volatility (10D)	49.03
Volatility (30D)	63.44
Free Float	91.05%

Analyst Consensus

N/A

Current Price $0.00

Mean Target N/A

52W Low$0.00 52W High$0.01

Current

Target

$0.00 $0.01

Current Analyst target

· 0 analysts

Identifiers

ExchangeLSE

FIGIBBG001S7SN00

ISINGB00BLH13C52

CountryUnited Kingdom

Sub-IndustryBio Therapeutic Drugs

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

ValiRx Plc is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of science into impactful medicines to improve patient lives. The Company provides the scientific, financial, and commercial framework for enabling rapid translation of science into clinical development. The Company selects and incubates novel drug candidates and guides them through an optimized process of development, from pre-clinical studies to clinical and investor-ready assets. Its product pipeline includes VAL201, VAL301, CLX001 and BC201. VAL201 is a short peptide being studied for the treatment of prostate cancer. VAL201 can prevent cancerous cell proliferation (or growth) without interfering with other functions of the androgen receptor or SRC kinase. CLX001 is a peptide in nanoparticle formulation and is designed for precision destruction of cancer cells to avoid excessive side effects.